HeartBeam (NASDAQ: BEAT), a medical technology company advancing cardiac care through actionable cardiac insights, announced the appointment of Bryan Humbarger as chief commercial officer, effective Jan. 22, 2026. In this newly created role, Humbarger will lead commercial strategy and execution across key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication, and a 12-lead ECG extended wear patch monitor. He will also expand outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption.
This appointment comes at a critical time for HeartBeam as it transitions from product development to commercial deployment. The company’s 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-Lead ECG synthesis software in December 2025, represents a novel approach to cardiac monitoring. The cable-free device collects ECG signals from three non-coplanar directions and synthesizes them into a standard 12-lead ECG, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities.
Humbarger brings extensive experience in commercializing medical technologies, having previously held leadership roles at major diagnostic and cardiovascular companies. His expertise in launching innovative products and building commercial teams will be instrumental as HeartBeam seeks to establish its platform in the cardiology market. The company’s strategy includes partnering with cardiology practices to demonstrate real-world efficacy and gather data to support broader reimbursement and adoption.
The limited launch of the HeartBeam System for arrhythmia assessment and heart attack detection is a key milestone. By focusing on these high-acuity indications, HeartBeam aims to address significant unmet needs in cardiac care. The device’s ability to provide actionable insights remotely could reduce hospital visits and enable earlier intervention for patients at risk of heart attacks or arrhythmias. The extended wear patch monitor further enhances patient monitoring capabilities, offering continuous ECG recording for up to 14 days.
HeartBeam’s technology has the potential to redefine cardiac health management by shifting diagnostics from clinical settings to patient-centric environments. The company’s 3D ECG platform is designed for portable devices that can be used wherever the patient is, delivering what the company calls “actionable heart intelligence.” This aligns with broader trends in telehealth and remote patient monitoring, which have gained traction due to their convenience and cost-effectiveness.
As HeartBeam expands its commercial footprint, it will need to navigate regulatory, reimbursement, and competitive challenges. The company’s forward-looking statements highlight risks such as market acceptance, clinical validation, and dependence on key personnel. However, the appointment of a seasoned executive like Humbarger signals a commitment to executing its commercial strategy effectively.
For more information about HeartBeam and its technology, visit the company’s newsroom at https://ibn.fm/BEAT. Full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
